Santosh Shripad Kulkarni

This inventor holds 53 USPTO granted patents and 16 published patent applications, plus 2 CIPO patents and 23 EPO patents, primarily in Glycosidase Inhibitors. Top assignees: Albireo Ab, Asceneuron Sa, Synopsys, Inc.. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Santosh Shripad Kulkarni. Retrieved from https://idiyas.com/inventor/santosh-shripad-kulkarni

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 53 (Patent Applications = 16)

% Patents Active = 92.5

CIPO Patents = 2 (Patent Applications = 17)

EPO Patents = 23 (Patent Applications = 32)

Average Co-Inventor Count = 3.5

ph-index = 12

Forward Citations = 411(Granted Patents)

Forward Citations (Not Self Cited) = 115(Dec 10, 2025)

Location History:

Karnataka, IN (2016 - 2019)
Bengaluru, IN (2013 - 2024)
Banglaore, IN (2024)

Company Filing History:

Astellas Engineered Small Molecules US, Incorporated

Syndax Pharmaceuticals, Inc.

Vitae Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Glycosidase Inhibitors

Piperazine Derivatives

Benzothiazepine Compounds

Benzothiadiazepine Compounds

Succinate Salts

Fumarate Salts

Spiro Compounds

PDE4 Activators

Sulfoximine Inhibitors

Linear Inhibitors

Annulated Inhibitors

Bile Acid Modulators

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12514858 - CD38 inhibitors (2026-01-06),

2. 12398130 - Acid addition salts of piperazine derivatives (2025-08-26),

3. 12365658 - Benzothia(di)azepine compounds and their use as bile acid modulators (2025-07-22),

4. 12202809 - Benzothia(di)azepine compounds and their use as bile acid modulators (2025-01-21),

5. 12195455 - Succinate and fumarate acid addition salts of piperazine derivatives (2025-01-14),

6. 12187741 - Glycosidase inhibitors (2025-01-07),

7. 12187690 - Benzothiadiazepine compounds and their use as bile acid modulators (2025-01-07),

8. 12157734 - Sulfoximine glycosidase inhibitors (2024-12-03),

9. 12134606 - Benzothia(di)azepine compounds and their use as bile acid modulators (2024-11-05),

10. 12060338 - Benzothia(di)azepine compounds and their use as bile acid modulators (2024-08-13),

11. 12024495 - Benzothiazepine compounds and their use as bile acid modulators (2024-07-02),

12. 12016852 - Pyrrolidine glycosidase inhibitors (2024-06-25),

13. 11919901 - Inhibitors of the menin-MLL interaction (2024-03-05),

14. 11891368 - Benzothia(di)azepine compounds and their use as bile acid modulators (2024-02-06),

15. 11795165 - Tetrahydro-benzoazepine glycosidase inhibitors (2023-10-24),

Title: **A Profile of Santosh Shripad Kulkarni: Innovator in Pharmaceutical Patents**

Introduction

Santosh Shripad Kulkarni, based in Bengaluru, India, is a prominent inventor and researcher whose contributions have significantly impacted the pharmaceutical industry. With an impressive portfolio of 46 patents, he specializes in innovations related to drug development, particularly in treating complex diseases.

Latest Patents

Kulkarni's recent patents showcase his innovative approach to addressing critical health issues. One notable invention is the sulfoximine glycosidase inhibitors, which consist of compounds that can be utilized in the treatment of tauopathies, including Alzheimer's disease. Additionally, he has developed benzothiazepine compounds, defined specifically for their role as bile acid modulators. These compounds exhibit inhibitory activity on the apical sodium-dependent bile acid transporter (ASBT) and liver bile acid transport (LBAT), offering potential therapeutic applications for cardiovascular diseases, fatty acid metabolism disorders, glucose utilization disorders, gastrointestinal diseases, and liver diseases.

Career Highlights

Throughout his career, Santosh has worked with esteemed companies such as Albireo Ab and Asceneuron Sa, where he has honed his expertise in pharmaceutical innovations. His work has not only advanced the understanding of metabolic disorders but also led to potential new treatment modalities for various diseases.

Collaborations

Kulkarni has collaborated with notable professionals in the field, including Per-Göran Gillberg and Ingemar Starke. These collaborations further exemplify his commitment to advancing pharmaceutical research and innovation.

Conclusion

In summary, Santosh Shripad Kulkarni stands out as a dedicated inventor in the pharmaceutical landscape. With his extensive patent portfolio and collaborative spirit, he continues to push the boundaries of innovation, making significant contributions towards the treatment of various diseases. His work serves as an inspiration for future generations of inventors aiming to improve healthcare through innovative solutions.

Profile summary based on public USPTO records.